Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Nivolumab in Recurrent/Metastatic SCCHN
NCT03652233Phase 1Withdrawn
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of afatinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Maximum Tolerated Dose up to 42 days, Dose Limiting Toxicities up to 42 days and 1 more. Planned start Nov 2018; status: withdrawn.
02
Drugs
afatinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03652233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652233.